![Dani Stoltzfus](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Dani Stoltzfus
Corporate Officer/Principal chez NEUBASE THERAPEUTICS, INC.
Profil
Dani Stoltzfus is currently working as Vice President-Research at NeuBase Therapeutics, Inc. She has an education background from Flinders University, where she completed her undergraduate, graduate, and doctorate degrees.
Postes actifs de Dani Stoltzfus
Sociétés | Poste | Début |
---|---|---|
NEUBASE THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formation de Dani Stoltzfus
Flinders University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
NeuBase Therapeutics, Inc.
![]() NeuBase Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on March 29, 2002 and is headquartered in Pittsburgh, PA. | Health Technology |